依维莫司药物涂层支架和佐他莫司药物涂层支架治疗冠心病的安全性和有效性的Meta分析

发布时间：2018-04-13 20:16

  本文选题：依维莫司 + 佐他莫司　； 参考：《广西医科大学》2017年硕士论文

【摘要】：目的:系统评价依维莫司药物涂层支架(Everolimus-eluting stents,EES)与佐他莫司药物涂层支架(Zotarolimus-eluting stents,ZES)治疗冠心病的安全性与有效性。方法:计算机检索PubMed、Web of science、The Cochrane Library、中国维普(VIP)、中国知网(CNKI)、中国生物医学(CBM)、万方数据库,纳入关于比较EES和ZES治疗冠心病患者的随机对照试验(Randomized controlled trial,RCTs)。由2位评价员独立评价并提取数据,按照Cochrane系统评价员手册(5.1.0版)评价纳入研究的质量,采用RevMan 5.3软件进行数据统计分析。结果:最终纳入6篇RCTs,总计10565例患者,其中EES组5913例,ZES组4652例。Meta分析结果显示:接受EES和ZES治疗的冠心病患者在全因死亡(RR=1.01,95%CI:0.85~1.20,P=0.91)、心源性死亡(RR=0.96,95%CI:0.76~1.21,P=0.73)、心肌梗死(RR=0.88,95%CI:0.75~1.02,P=0.10)、确定的和很可能的支架内血栓(RR=0.79,95%CI:0.53~1.17,P=0.24)、主要不良心血管事件(RR=0.97,95%CI:0.86~1.09,P=0.59)、靶病变血运重建(RR=0.87,95%CI:0.72~1.03,P=0.11)、靶血管血运重建(RR=0.94,95%CI:0.81~1.10,P=0.47)、面向设备的复合终点(RR=0.95,95%CI:0.83~1.08,P=0.43)、面向患者的复合终点(RR=0.96,95%CI:0.88~1.06,P=0.43)等方面的差异均无统计学意义。结论:结果表明,EES和ZES在治疗冠心病患者时安全性与有效性相当,但需要更多的大型随机临床试验来进一步证实。
[Abstract]:Aim: to evaluate the safety and efficacy of Everolimus-eluting stentsEES and Zotarolimus-eluting stentsZESs in the treatment of coronary heart disease.Methods: a computer-based search was conducted on the Cochrane Library of PubMeda, VIPP, CNKIJ, CBMN, and Wanfang database, respectively. A randomized controlled trial was conducted to compare EES and ZES in the treatment of coronary heart disease (CHD) patients in a randomized controlled trial (Randomized controlled trialator).The data were evaluated and extracted by two evaluators, and the quality of the study was evaluated according to the Cochrane system evaluator manual (version 5.1.0). The data were analyzed by RevMan 5.3 software.Results: a total of 10565 patients were included in 6 RCTs.The results of meta-analysis of 4652 patients with coronary heart disease treated with EES and ZES in EES group (5913 cases) showed that the total death rate of patients with coronary heart disease was RR1.01C 1.01N 95 CI: 0.851.20 P0.91, RR0.961.21CI: 0.761.21P0.73, RRN 0.8895 CI: 0.751.02P0.100.The determined and probable intracardiac thrombus was RR0.7995CI0.530.97CI0.530.17P0.24N, and the main adverse cardiovascular events were found to be the main adverse cardiovascular events.Conclusion: the results suggest that the safety and efficacy of EES and ZES in the treatment of coronary heart disease patients are similar, but more large randomized clinical trials are needed to further confirm.
【学位授予单位】：广西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R541.4

【参考文献】

中国期刊全文数据库 前1条

1 曾宪涛;包翠萍;曹世义;刘菊英;;Meta分析系列之三:随机对照试验的质量评价工具[J];中国循证心血管医学杂志;2012年03期

，

本文编号：1746035